Standardized SEC financial data for ZIMMER BIOMET HOLDINGS, INC. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001136869 · NYSE · Orthopedic, Prosthetic & Surgical Appliances & Supplies.
Ratios for fiscal year 2025, standardized from SEC filings.
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $6.13B | $6.83B | $6.94B | $7.39B | $7.68B | $8.23B |
| Cost of revenue | $1.82B | $1.96B | $2.02B | $2.08B | $2.19B | $2.49B |
| Gross profit | $4.30B | $4.87B | $4.92B | $5.31B |
| USD | FY2021 | FY2022 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $378.1M | — | $375.7M | $415.8M | $525.5M | $591.9M |
| Inventory | $2.15B | — | $2.15B | $2.39B | $2.24B | $2.29B |
| Total current assets | $4.88B | — | $4.43B | $4.61B |
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $1.20B | $1.50B | $1.36B | $1.58B | $1.50B | $1.70B |
| Capital expenditures | $111.9M | $143.6M | $187.9M | $291.1M | $203.8M | $224.5M |
| Free cash flow | $1.09B | $1.36B | $1.17B | $1.29B |
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/ZBH/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/ZBH/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"| $5.49B |
| $5.74B |
| R&D expense | $322.8M | $435.8M | $406.0M | $458.7M | $437.4M | $458.5M |
| SG&A expense | $2.71B | $2.84B | $2.76B | $2.84B | $2.93B | $3.26B |
| Operating income | $83.1M | $860.3M | $696.3M | $1.28B | $1.29B | $1.10B |
| EBITDA | $981.5M | $1.80B | $1.62B | $2.23B | $2.28B | $2.19B |
| Interest expense | $193.1M | $219.0M | $161.7M | $200.6M | $200.8M | $298.4M |
| Pretax income | -$274.4M | $499.0M | $403.5M | $1.07B | $1.04B | $830.8M |
| Income tax | $96.0M | $53.5M | $112.3M | $42.2M | $131.4M | $125.7M |
| Net income | -$138.9M | $401.6M | $231.4M | $1.02B | $903.8M | $705.1M |
| EPS (diluted) | $-0.67 | $1.91 | $1.10 | $4.88 | $4.43 | $3.55 |
Standardized from ZIMMER BIOMET HOLDINGS, INC.'s SEC filings — per-share figures split-adjusted. Full history via the API.
| $4.67B |
| $5.12B |
| Property, plant & equipment | $1.84B | — | $1.87B | $2.06B | $2.05B | $2.21B |
| Goodwill | $8.92B | $48.3M | $8.58B | $8.82B | $8.95B | $9.95B |
| Total assets | $23.46B | — | $21.07B | $21.50B | $21.37B | $23.09B |
| Total current liabilities | $3.47B | — | $2.36B | $2.86B | $2.45B | $2.58B |
| Long-term debt | $5.46B | — | $5.15B | $4.87B | $5.34B | $6.93B |
| Total debt | $7.07B | — | $5.70B | $5.77B | $6.20B | $7.52B |
| Total liabilities | $10.79B | — | $9.04B | $9.01B | $8.89B | $10.39B |
| Retained earnings | $10.29B | — | $9.56B | $10.38B | $11.10B | $11.61B |
| Total equity | $12.67B | — | $12.03B | $12.49B | $12.48B | $12.71B |
| $1.30B |
| $1.47B |
| Investing cash flow | -$613.8M | -$503.6M | -$522.0M | -$778.9M | -$888.1M | -$1.98B |
| Financing cash flow | -$421.8M | -$1.31B | -$775.7M | -$763.5M | -$484.5M | $326.0M |
| Dividends paid | $198.9M | $200.4M | $201.3M | $200.9M | $196.0M | $190.3M |
| Share repurchases | — | — | $126.4M | $692.2M | $868.0M | $487.0M |